Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
- Conditions
- Contraception
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Femasys Inc.
- Target Recruit Count
- 573
- Registration Number
- NCT05977751
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸University of California Davis, Sacramento, California, United States
🇺🇸Midtown OB GYN North, Columbus, Georgia, United States
FemaSeed LOCAL Artificial Insemination Trial
- Conditions
- Male FactorInfertility
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Femasys Inc.
- Target Recruit Count
- 314
- Registration Number
- NCT04968847
- Locations
- 🇺🇸
Elite IVF, PLLC, Mobile, Alabama, United States
🇺🇸Reproductive Associates of Delaware (RAD Fertility), Newark, Delaware, United States
🇺🇸Women's Medical Research Group, LLC, Clearwater, Florida, United States
FemBloc® Permanent Contraception - Confirmation Feasibility Trial
- Conditions
- Contraception
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Femasys Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04273594
- Locations
- 🇺🇸
New Horizons Clinical Trials, Chandler, Arizona, United States
🇺🇸Precision Trials AZ, LLC, Phoenix, Arizona, United States
🇺🇸Midtown OB GYN North, Columbus, Georgia, United States
FemBloc® Permanent Contraception - Early Pivotal Trial
- Conditions
- Contraception
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Femasys Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT03433911
- Locations
- 🇺🇸
New Horizons Clinical Trials, Chandler, Arizona, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Altus Research Inc., Lake Worth, Florida, United States
Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception
- Conditions
- Contraception
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Femasys Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03067272
- Locations
- 🇺🇸
Altus Research Inc., Lake Worth, Florida, United States
🇺🇸New York Presbyterian Hospital - Columbia University Medical Center, New York, New York, United States
🇺🇸University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States
- Prev
- 1
- 2
- Next
News
Femasys Receives World's First Regulatory Approval for Non-Surgical Permanent Birth Control System in Europe
Femasys Inc. achieved CE mark certification for its complete FemBloc System, marking the first global regulatory approval for non-surgical permanent female birth control.
Femasys Partners with Carolinas Fertility Institute to Expand FemaSeed Access Across North Carolina Network
Femasys Inc. announced a partnership with Carolinas Fertility Institute to offer FemaSeed intratubal insemination across CFI's network of more than 8 locations in North Carolina.
FemBloc Non-Surgical Birth Control Shows 100% Effectiveness in Clinical Trials with Five-Year Safety Data
Clinical trials of FemBloc, a novel non-surgical permanent birth control method, demonstrated 0% pregnancy rate among eligible participants, significantly outperforming the 6% benchmark for surgical sterilization.
Femasys Receives FDA Clearance for FemChec Fallopian Tube Diagnostic
Femasys Inc. has received FDA 510(k) clearance for FemChec, a diagnostic solution designed for checking the fallopian tubes using controlled contrast delivery.